Q2 2025 Alvotech SA Earnings Call Transcript
Key Points
- Alvotech (ALVO) reported a 30% year-on-year increase in revenues for the first half of 2025, reaching $306 million.
- The company achieved a 200% growth in product revenues in the first half of the year, with a 77% increase in the second quarter alone.
- Alvotech (ALVO) delivered its fifth consecutive quarter of positive adjusted EBITDA, demonstrating consistent financial performance.
- The company has expanded its market presence, with its Humira biosimilar now being sold in 33 markets globally and approved in 67 markets.
- Alvotech (ALVO) has strengthened its R&D capabilities by acquiring the R&D operations of Xbrane in Stockholm and securing rights to a biosimilar candidate referencing Cimzia.
- Licensing revenues decreased from $170 million in the first half of 2024 to $101 million in the first half of 2025, due to the timing of development milestones.
- Adjusted EBITDA for the first half of 2025 was $54 million, down from $64 million in the same period last year, impacted by lower licensing revenues.
- The company anticipates a softer performance in Q3 2025, with expectations of stronger results in Q4, indicating potential volatility in quarterly earnings.
- Alvotech (ALVO) faces competitive pricing pressures in the STELARA biosimilar market, which could impact long-term profitability.
- Despite strong market share in the U.S. for its Humira biosimilar, the company acknowledges challenges in maintaining growth in the Quallent channel.
Good day, and thank you for standing by. Welcome to the Alvotech Second Quarter 2025 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Benedikt Stefansson, Vice President of Investor Relations and Global Communications. Please go ahead, sir.
Thank you, and welcome to our listeners. Yesterday evening, the company issued a press release announcing our financial results for the first 6 months of 2025. A presentation accompanying today's earnings call was also published last night on our investor portal, investors.alvotech.com under News and Events. We will be referring to individual slides during the presentation today. Our press release, presentation and statements that we make on the call today may include forward-looking statements.
Please see our disclaimers on Slide #2 of the presentation. These statements do not ensure future performance and are subject to risks and uncertainties that are outlined in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
